JPM 2026 made one thing clear: biotech is shifting from strategic storytelling to execution strategy. Across conversations with founders, operators, and investors, the focus was on building real, scalable plans that hold up under pressure, from phase-appropriate CMC strategy to regulatory readiness, quality infrastructure, and commercialization planning. With that in mind, here are the key themes we heard repeatedly throughout the week, and what they signal for teams building in 2026.
- The tone shifted from pitching to building. JPM felt more operator-driven this year. Fewer “big idea” conversations, and more discussions centered on execution, timelines, and real decision-making.
- Capital is moving again, but with intention. Funding isn’t flowing freely, but it is flowing to companies that show focus, readiness, and a clear path forward. The bar is higher, and diligence expectations are sharper.
- CMC is no longer a “later problem”. CMC strategy is increasingly being treated as a valuation driver, especially for complex modalities like fusion proteins, peptides, cell and gene therapies, and combination products. Teams are prioritizing CMC earlier because it directly impacts confidence, speed, and deal momentum.
- Phase-appropriate CMC plans are becoming a differentiator. Investors and partners are looking for CMC strategies that are coherent, scalable, and defensible, not just technically sound. The strongest plans support:
- scale-up across indications
- multiple commercial pathways
- scrutiny during diligence, not just storytelling
- “Lean teams + aggressive timelines” is the new normal. A consistent pattern: small teams running multiple assets with ambitious milestones. Leaders are feeling pressure to do more with less, and to move faster without breaking quality or compliance.
- Quality systems are being pulled forward. Companies are accelerating work that used to wait until later stage, including quality infrastructure and operational readiness, because partners and regulators expect maturity earlier than they used to.
- Regulatory uncertainty is creating real anxiety. There was significant concern around the evolving U.S. regulatory landscape, and a strong demand for support with:
- FDA engagement planning
- qSub strategy and checklists
- regulatory roadmaps that hold up under pressure
- Fractional leadership and integrated execution are now survival strategies. More companies acknowledged that “we’ll build it internally later” does not work anymore. There is growing demand for single-source accountability and integrated support across CMC, regulatory, and operational strategy.
- Not everyone feels the market rebound. While some optimism is returning, it was not universal. Several founders still described capital raising as unchanged from last year, with continued friction engaging investors.
- The bottom line: biotech is not for the faint of heart, the stakes are high, and it takes both thoughtful strategy and execution to survive. This year felt more grounded and more disciplined. The winners are building value through risk reduction, operational clarity, and execution strength.
The companies that will win in 2026 and beyond are not the loudest, they are the most prepared. Strong science still matters, but disciplined execution is what protects valuation, accelerates timelines, and creates optionality across development and commercial pathways. If your team is navigating lean resourcing, complex modalities, or heightened regulatory expectations, SynerG can help you build the integrated roadmap and operational foundation needed to move forward with clarity. From fractional leadership and end-to-end CMC planning to FDA engagement strategy and quality systems built to scale, we bring the expertise and accountability to help you execute what matters most.
